Food Allergy Fund Supports Efforts to End Food Allergies and Other Chronic Diseases
NEW YORK--(BUSINESS WIRE)--The Food Allergy Fund applauds the release of the Make America Healthy Again report, which provides a roadmap for addressing the childhood chronic disease crisis, and thanks the MAHA Commission for prioritizing bold, science-driven solutions to address the health challenges, such as food allergies, that face our children.
By investing in research to better understand and address food allergies, we can unlock new insights with the potential to reshape the future of public health.
Share
'Food allergies are a serious and rapidly growing public health crisis, affecting more than 33 million Americans—including 1 in 13 children and 1 in 10 adults. They serve as an early warning sign of broader chronic disease trends and sit at the critical intersection of food and agriculture, immune function, metabolic health, and the microbiome. By investing in research to better understand and address food allergies, we can unlock new insights with the potential to reshape the future of public health.
'We commend the Administration's dedication to fostering innovation to tackle chronic disease and improve health in America. We appreciate the dialogue already underway with leadership and support collaboration to drive forward research that addresses the root causes of allergic disease and related conditions, delivering meaningful solutions for Americans.'
About the Food Allergy Fund
The Food Allergy Fund (FAF) is the leading nonprofit dedicated to funding cutting-edge research to prevent, diagnose, and treat food allergies, a growing public health crisis affecting 10 percent of people in the United States and more than 300 million globally. Through innovative research grants and thought leadership summits, FAF is an incubator and convener, uniting scientists, policymakers, industry leaders, and entrepreneurs to drive breakthroughs. FAF's mission is to create a future where no one has to suffer from food allergies. To learn more, visit www.foodallergyfund.org.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
20 minutes ago
- Bloomberg
Republicans May Find They Need to Get Behind the ACA
House Republicans' reconciliation bill seeks to pay for $5 trillion of tax cuts by slashing health-care spending, potentially leaving millions of Americans uninsured. The job of averting this self-inflicted disaster now falls to the Senate. The legislation seeks to cut $793 billion from Medicaid, the health program for the poor. Half this sum will come from requiring beneficiaries under 65 to work, look for employment or volunteer, with some exemptions. The new rules are slated to start in late 2026 — moved up from 2029 — after some lawmakers objected that savings wouldn't materialize soon enough.
Newsweek
27 minutes ago
- Newsweek
RFK Jr. Bombarded Bill Nye with Autism Texts, TV Scientist Says
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. TV scientist Bill Nye said he cut Robert F. Kennedy Jr. off after the now-health secretary bombarded him with text messages about autism. The host of Bill Nye the Science Guy, whose show has educated millions of viewers about science, spoke about Kennedy in a new interview with Men's Health. Newsweek has contacted the United States Department of Health and Human Services, via email, for a response. Why It Matters Kennedy has long faced backlash for some of his positions on health and medicine, especially vaccines. During his Senate confirmation in January, Kennedy insisted that he was not anti-vaccine, that he believes vaccines "play a critical role in healthcare." Critics say Kennedy's agenda undermines the scientific process and risks eroding decades of public trust in vaccines, while others argue that his new approach is what Americans voted for. (R) U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. attends President Donald Trump's address to a joint session of Congress at the U.S. Capitol on March 04, 2025 in Washington, D.C. (L)... (R) U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. attends President Donald Trump's address to a joint session of Congress at the U.S. Capitol on March 04, 2025 in Washington, D.C. (L) Bill Nye attends the arrivals of Sierra Club's 2025 Trail Blazers Ball at the Skirball Cultural Center in Los Angeles, CA on April 2, 2025 More Win McNamee//Sipa via AP Images What To Know Nye, who met Kennedy before he became health secretary, through their mutual actor friend Ed Begley Jr., showed what Men's Health reporter Chantel Anderson described as "miles and miles of texts" from Kennedy with "few interruptions, screen after screen." "Just no self-awareness," Nye said. "And if you read these articles he sent, they're all this speculation about autism and just cause-and-effect, and mercury in vaccines, that maybe there's a connection." Nye said he replied to Kennedy, "Okay, I'll read your book. I think you've confused causation with correlation. Your friend, Bill." But, when Kennedy responded with "more miles of texts," Nye told him: "Okay, no more texts." "And he started again," Nye said, "so I cut him off." He added that Kennedy doesn't have "good judgement" and is "not suited" to be health secretary. Nye went on to speak about the measles outbreak in Texas, where 744 cases have been confirmed since late January, according to the Texas Department of State Health Services. Kennedy has faced criticism from both anti-vax activists and advocates of vaccines. In March, he sparked anger from anti-vax activists when he called on parents to "consult with their healthcare providers to understand their options to get the MMR vaccine," with one saying he is "no different than Fauci." But he has also faced backlash from those in favor of vaccines for some of his comments, including when he told Fox News: "When you and I were kids, everybody got measles, and measles gave you ... lifetime protection against measles infection. The vaccine doesn't do that. The vaccine is effective for some people for life, but for many people, it wanes." Director of the Vaccine Education Center at Children's Hospital of Philadelphia, Dr. Paul Offit, told HealthDay that this could not be true given that measles was declared eliminated in America in 2000. Health and Human Services Secretary Robert F. Kennedy Jr., testifies before a Senate Committee on Appropriations subcommittee hearing to examine proposed budget estimates for fiscal year 2026 for the Department of Health and Human Services,... Health and Human Services Secretary Robert F. Kennedy Jr., testifies before a Senate Committee on Appropriations subcommittee hearing to examine proposed budget estimates for fiscal year 2026 for the Department of Health and Human Services, on Capitol Hill, Tuesday, May 20, 2025, in Washington. More AP What People Are Saying Kennedy said during his confirmation hearing, while arguing that he is not anti-vaccine: "In my advocacy, I've often disturbed the status quo by asking uncomfortable questions. Well, I'm not going to apologize for that – we have massive health problems in this country that we must face honestly." Nye said in his interview with Men's Health: "I went to elementary school with a guy who had polio. You do not want polio! And the reason you don't get polio is because of a vaccine that was discovered that keeps you from getting polio! What is wrong with you, man?" What Happens Next Kennedy is yet to respond to Nye's comments about him. It comes as the health secretary announced eight new experts on a panel that advises the Centers for Disease Control and Prevention.
Yahoo
an hour ago
- Yahoo
Weight-loss drugs were said to be a game changer. Turns out the benefit might be thinner than thought
Common GLP-1 weight loss drugs - including Wegovy and Ozempic - may not work for everyone in a 'real-world' setting, Cleveland Clinic researchers said Tuesday. The reason is that patients may take lower dosages or discontinue their treatment, negatively impacting the ability to control blood sugar levels in those who are pre-diabetic. The findings may have implications for people considering using the drugs, that are taken by more than eight million Americans every year. They've offered an alternative to traditional and taxing weight loss methods, such as diets and fitness. 'Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials,' Dr. Hamlet Gasoyan, a researcher with Cleveland Clinic, said in a statement. 'According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.' Gasoyan was the lead author of the study published on Tuesday in the Obesity Journal. 'Semaglutide has been extensively examined in robust clinical development programs, large real-world-evidence studies and has cumulatively over 33 million patient years of exposure,' a Novo Nordisk spokesperson told The Independent. 'Semaglutide's efficacy and safety have been extensively demonstrated in people with obesity/overweight with robust evidence for improving health outcomes. Semaglutide has demonstrated improvements in cardiovascular death, stroke, and myocardial infarction.' A request for comment from Eli Lilly was not immediately returned to The Independent. The study focuses on drugs with the active ingredients semaglutide and tirzepatide; they include the U.S. Food and Drug-administration approved type 2 diabetes medications Zepbound and Mounjaro. The authors studied their effects on weight loss and blood sugar regulation in a real-world setting. They noted that previous randomized clinical trials have shown the efficacy of those medications. The authors monitored the health of nearly 7,900 adults who were severely obese. Of those, more than 1,300 had pre-diabetes at the study's start and were at a higher risk for developing type 2 diabetes: a chronic condition that affects a person's ability to use insulin and keep blood sugar at normal levels. Participants took the shots between 2021 and 2023. The researchers sorted patients who discontinued their obesity medications into two groups: those who did it within just three months and by three months to a year. The study's follow-up period ended last December. The most common reasoning for discontinuation of treatment in the real-world setting was due to the steep cost of the drugs and insurance, side effects and shortages. Notably, since the study's, prices have started to fall. Of the participants, more than 20 percent discontinued their medications early and 32 percent discontinued their medications late. Furthermore, the authors noted than more than 80 percent had been on the lower dosages needed to sustain a therapeutic effect. For semaglutide, that's equal to or less than 1 milligram and equal to or less than 7.5 milligrams for tirzepatide. Following a year of treatment, the average weight reduction was 3.6 percent among participants who discontinued their treatment early, compared to 6.8 percent for those who discontinued their treatment late. But, those who did not discontinue treatment and were on the highest dosages necessary lost the most weight, at up to 13.7 percent with semaglutide and 18 percent with tirzepatide. Participants had higher odds of achieving 10 percent or greater weight reduction after one year of treatment if they did not discontinue their medications or did so late, were on the highest dosages needed for a therapeutic effect, received tirzepatide, and were women. Tracking the maintenance of blood sugar levels in those with pre-diabetes, the researchers said just a third of those who discontinued their treatment early experienced normal blood sugar levels compared to 41 percent who discontinued their treatment late and 67.9 percent who did not discontinue treatment. Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight compared to those who did not, their weight trajectories remained relatively stable. They said that would be the subject of additional research. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' explained Gasoyan.
